Duration of Antibiotic Therapy in Non-cystic Fibrosis Bronchiectasis
Authors:
- 26 November 2019
- journal article
- research article
- Published by Springer Nature in Current Pulmonology Reports
- Vol. 8 (4) , 160-165
Abstract
Purpose of Review We conducted a review of the current evidence relating to antibiotic duration in the short- and long-term management of non-cystic fibrosis bronchiectasis. Recent Findings In non-cystic fibrosis pulmonary exacerbations, evidence is primarily based on expert consensus and recent guidelines recommend antibiotic durations of approximately 14 days. Chronic antibiotics (oral or inhaled) are recommended in patients with frequent exacerbations or with chronic Pseudomonas aeruginosa airways infection. Macrolides are the best studied therapies for long-term use with evidence for effect limited to a 12-month duration. Encouragingly, there are increased efforts to develop registries and conduct larger population-level studies to improve patient care. Summary There is a paucity of evidence for optimal antibiotic strategies in exacerbations and chronic maintenance in persons with non-cystic fibrosis bronchiectasis. Rationally designed studies which utilize a registry and population-based approach will be critical to build evidence-based strategies to optimize management of non-cystic fibrosis bronchiectasis.Keywords
This publication has 54 references indexed in Scilit:
- Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lungNature, 2012
- Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasisRespiratory Medicine, 2012
- The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility TestsJournal of Clinical Microbiology, 2011
- British Thoracic Society guideline for non-CFbronchiectasisThorax, 2010
- Mortality in bronchiectasis: a long-term study assessing the factors influencing survivalEuropean Respiratory Journal, 2009
- Assessing response to treatment of exacerbations of bronchiectasis in adultsEuropean Respiratory Journal, 2008
- Prevalence and Economic Burden of BronchiectasisClinical Pulmonary Medicine, 2005
- The Impact of Antimicrobial Resistance on Health and Economic OutcomesClinical Infectious Diseases, 2003
- Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factorsThorax, 2002
- Prolonged Antibiotic Treatment of Severe BronchiectasisBMJ, 1957